The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020
Open accessAbstract
Following its emergence in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic resulting in unprecedented efforts to reduce transmission and develop therapies and vaccines (WHO Emergency Committee, 2020; Zhu et al., 2020). Rapidly generated viral genome sequences have allowed the spread of the virus to be tracked via phylogenetic analysis (Worobey et al., 2020; Hadfield et al., 2018; Pybus et al., 2020). While the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced, allowing continent-specific variants to emerge. However, within Europe travel resumed in the summer of 2020, and the impact of this travel on the epidemic is not well understood. Here we report on a novel SARS-CoV-2 variant, 20E (EU1), that emerged in Spain in early summer, and subsequently spread to multiple locations in Europe. We find no evidence of increased transmissibility of this variant, but instead demonstrate how rising incidence in Spain, resumption of travel across Europe, and lack of effective screening and containment may explain the variant’s success. Despite travel restrictions and quarantine requirements, we estimate 20E (EU1) was introduced hundreds of times to countries across Europe by summertime travellers, likely undermining local efforts to keep SARS-CoV-2 cases low. Our results demonstrate how a variant can rapidly become dominant even in absence of a substantial transmission advantage in favorable epidemiological settings. Genomic surveillance is critical to understanding how travel can impact SARS-CoV-2 transmission, and thus for informing future containment strategies as travel resumes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the first pandemic where the spread of a viral pathogen has been globally tracked in near real-time using phylogenetic analysis of viral genome sequences (Worobey et al., 2020; Hadfield et al., 2018; Pybus et al., 2020). SARS-CoV-2 genomes continue to be generated at a rate far greater than for any other pathogen and more than 500,000 full genomes are available on GISAID as of February 2020 (Shu and McCauley, 2017). In addition to tracking the viral spread, these genome sequences have been used to monitor mutations which might change the transmission, pathogenesis, or anti-genic properties of the virus. One mutation in particular, D614G in the spike protein, has received much attention. This variant (Nextstrain clade 20A) seeded large outbreaks in Europe in early 2020 and subsequently dominated the outbreaks in the Americas, thereby largely replacing previously circulating lineages. This rapid rise led to the suggestion that this variant is more transmissible, which has since been corroborated by phylogenetic (Korber et al., 2020; Volz et al., 2020) and experimental evidence (Plante et al., 2020; Yurkovetskiy et al., 2020). Following the global dissemination of SARS-CoV-2 in early 2020 (Worobey et al., 2020), intercontinental travel dropped dramatically. Within Europe, however, travel and in particular holiday travel resumed in summer (though at lower levels than in previous years) with largely uncharacterized effects on the pandemic. Here we report on a novel SARS-CoV-2 variant 20E (EU1) ( S:A222V ) that emerged in early summer 2020, presumably in Spain, and subsequently spread to multiple locations in Europe. Over the summer, it rose in frequency in parallel in multiple countries. As we report here, this variant, 20E (EU1), and a second variant 20A.EU2 with mutation S477N in the spike protein accounted for the majority of sequences in Europe in the autumn of 2020.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
Katoh, K. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf436 · Cited by 17,027 · cited 1×
“In some cases only a single 20A.EU1 genotype was sampled in a country, but in many countries multiple distinct genotypes were sampled, indicating multiple in-troductions, and these we will cover in more detail below.”
IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era
Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., & Lanfear, R. (2020) · Molecular Biology and Evolution · doi:10.1093/molbev/msaa015 · Cited by 16,873
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citationBEAST 2.5: An advanced software platform for Bayesian evolutionary analysis
Bouckaert, R., Vaughan, T. G., Barido-Sottani, J., Duchêne, S., Fourment, M., Gavryushkina, A., Heled, J., Jones, G., Kühnert, D., De Maio, N., et al. (2019) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006650 · Cited by 4,556
Self-citationKorber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281 · cited 3×
“This rapid rise has led to the suggestion that this variant is more trans-. missible (Korber et al. , 2020; Volz et al. , 2020), which is corroborated by experimental studies (Plante et al. , 2020; Yurkovetskiy et al. , 2020).”
Nextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
Self-citationGISAID: Global initiative on sharing all influenza data – from vision to reality
Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039
Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases
Mossong, J., Hens, N., Jit, M., Beutels, P., Auranen, K., Mikolajczyk, R., Massari, M., Salmaso, S., Tomba, G. S., Wallinga, J., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050074 · Cited by 2,900
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · cited 3×
“All viruses were titered in 293T-ACE2 cells (BEI NR-52511) as described in (Crawford et al. , 2020), with the following modifications.”
Self-citationCross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Self-citationSARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599 · cited 5×
“While none of these have reached the prevalence of 20A.EU1 or 20A.EU2, some have attracted attention in their own right: S:N439K has appeared twice in the pandemic (Thomson et al. , 2020), is found across Europe (particularly Ireland and the UK), is located in the RBD, and is an escape mutation from antibody C135 (Bar…”
InfluentialSpike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558 · cited 4×
“This rapid rise has led to the suggestion that this variant is more trans-. missible (Korber et al. , 2020; Volz et al. , 2020), which is corroborated by experimental studies (Plante et al. , 2020; Yurkovetskiy et al. , 2020).”
InfluentialA neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308
TreeTime: Maximum-likelihood phylodynamic analysis
Sagulenko, P., Puller, V., & Neher, R. A. (2018) · Virus Evolution · doi:10.1093/ve/vex042 · Cited by 1,186
Self-citationStructural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T. P., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.032 · Cited by 1,025 · cited 4×
“…from antibody C135 (Barnes et al. , 2020; Weisblum et al. , 2020) and S:Y453F , also in the RBD, has appeared multiple times, may be an adaptation to mink (Rodrigues et al. , 2020), is also an escape mutation for an antibody (Baum et al. , 2020), and was associated with an out-break in Danish mink.”
InfluentialGreaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016
Self-citationEvaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.020 · Cited by 1,006
The genomic and epidemiological dynamics of human influenza A virus
Rambaut, A., Pybus, O. G., Nelson, M. I., Viboud, C., Taubenberger, J. K., & Holmes, E. C. (2008) · Nature · doi:10.1038/nature06945 · Cited by 925
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901
Self-citationCrawford, K. H. D., Eguia, R., Dingens, A. S., Loes, A. N., Malone, K. D., Wolf, C. R., Chu, H. Y., Tortorici, M. A., Veesler, D., Murphy, M., et al. (2020) · Viruses · doi:10.3390/v12050513 · Cited by 776
Self-citationEmergence of genomic diversity and recurrent mutations in SARS-CoV-2
van Dorp, L., Acman, M., Richard, D., Shaw, L. P., Ford, C. E., Ormond, L., Owen, C. J., Pang, J., Tan, C. C. S., Boshier, F. A. T., et al. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104351 · Cited by 774
Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK
CMMID COVID-19 working group, Jarvis, C. I., Van Zandvoort, K., Gimma, A., Prem, K., Klepac, P., Rubin, G. J., & Edmunds, W. J. (2020) · BMC Medicine · doi:10.1186/s12916-020-01597-8 · Cited by 720
The coding capacity of SARS-CoV-2
Finkel, Y., Mizrahi, O., Nachshon, A., Weingarten-Gabbay, S., Morgenstern, D., Yahalom-Ronen, Y., Tamir, H., Achdout, H., Stein, D., Israeli, O., et al. (2021) · Nature · doi:10.1038/s41586-020-2739-1 · Cited by 644
Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606
Self-citationGenetic Variants of SARS-CoV-2—What Do They Mean?
Lauring, A. S., & Hodcroft, E. B. (2021) · JAMA · doi:10.1001/jama.2020.27124 · Cited by 604
Self-citationStadler, T., Kühnert, D., Bonhoeffer, S., & Drummond, A. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207965110 · Cited by 541
Self-citationWalls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
Self-citationUltrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., et al. (2020) · Science · doi:10.1126/science.abe3354 · Cited by 510
Self-citationMinh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., & Lanfear, R. (2020) · Molecular Biology and Evolution · doi:10.1093/molbev/msaa131 · Cited by 408
The emergence of SARS-CoV-2 in Europe and North America
Worobey, M., Pekar, J., Larsen, B. B., Nelson, M. I., Hill, V., Joy, J. B., Rambaut, A., Suchard, M. A., Wertheim, J. O., & Lemey, P. (2020) · Science · doi:10.1126/science.abc8169 · Cited by 358
Making Sense of Mutation: What D614G Means for the COVID-19 Pandemic Remains Unclear
Grubaugh, N. D., Hanage, W. P., & Rasmussen, A. L. (2020) · Cell · doi:10.1016/j.cell.2020.06.040 · Cited by 353
Potential impact of seasonal forcing on a SARS-CoV-2 pandemic
Neher, R. A., Dyrdak, R., Druelle, V., Hodcroft, E. B., & Albert, J. (2020) · Swiss Medical Weekly · doi:10.4414/smw.2020.20224 · Cited by 286
Self-citationMcCallum, M., Walls, A. C., Bowen, J. E., Corti, D., & Veesler, D. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0483-8 · Cited by 173
Self-citationCorrea-Martínez, C. L., Kampmeier, S., Kümpers, P., Schwierzeck, V., Hennies, M. T., Hafezi, W., Kühn, J., Pavenstädt, H. J., Ludwig, S., & Mellmann, A. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.00588-20 · Cited by 113
The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans
Pancer, K., Milewska, A., Owczarek, K., Dabrowska, A., Kowalski, M., Łabaj, P. P., Branicki, W., Sanak, M., & Pyrc, K. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008959 · Cited by 83
High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl
Knabl, L., Mitra, T., Kimpel, J., Rössler, A., Volland, A., Walser, A., Ulmer, H., Pipperger, L., Binder, S. C., Riepler, L., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00007-1 · Cited by 77
The emergence of SARS-CoV-2 in Europe and the USPreprint
Worobey, M., Pekar, J. E., Larsen, B. B., Nelson, M. I., Hill, V., Joy, J. B., Rambaut, A., Suchard, M. A., Wertheim, J. O., & Lemey, P. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.21.109322 · Cited by 63
Stange, M., Mari, A., Roloff, T. C., Seth-Smith, H. M. B., Schweitzer, M., Brunner, M., Leuzinger, K., Søgaard, K. K., Gensch, A., Tschudin‐Sutter, S., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009374 · Cited by 44
Quantifying SARS-CoV-2 spread in Switzerland based on genomic sequencing dataPreprint
Nadeau, S., Beckmann, C., Topolsky, I., Vaughan, T. G., Hodcroft, E. B., Schär, T., Nissen, I., Santacroce, N., Burcklen, E., Ferreira, P., et al. (2020) · medRxiv · doi:10.1101/2020.10.14.20212621 · Cited by 10
Self-citation
Research works printed but not linked: 9
- 2017, Eurosurveillance, 22, 30494
- 2020, Nature Microbiology, 5, 1403
- 2020, eLife, 9, e61312
- 2020, PLOS Pathogens, 16, e1008959
- 2008, PLOS Medicine, 5, e74
- N. G. Davies , R. C. Barnard , C. I. Jarvis , A. J. Kucharski , J. Munday , C. A. B. Pearson , T. W. Russell , D. C. Tully , S. Abbott , A. Gimma , W. Waites , K. L. Wong , K. v. Zandvoort , C. C.-. W. Group , R. M. Eggo , S. Funk , M. Jit , K. E. Atkins , W. J. Edmunds , Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England, medRxiv (2020) 2020.12.24.20248822. Publisher: Cold Spring Harbor Laboratory Press.
- M. Stange , A. Mari , T. Roloff , H. M. B. Seth-Smith , M. Schweitzer , M. Brunner , K. Leuzinger , K. K. Sogaard , A. Gensch , S. Tschudin-Sutter , S. Fuchs , J. A. Bielicki , H. Pargger , M. Siegemund , C. H. Nickel , R. Bingisser , M. Osthoff , S. Bassetti , R. Schneider-Sliwa , M. Battegay , H. H. Hirsch , A. Egli , SARS-CoV-2 phylogeny during the early outbreak in the Basel area, Switzerland: import and spread dominated by a single B.1 lineage vari-ant (C15324T), medRxiv (2020) 2020.09.01.20186155. Publisher: Cold Spring Harbor Laboratory Press. · DOI
- 2019, PLOS Computational Biology, 15, e1006650
- 2020, Viruses, 12, 513
Cited by
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
“126) 51 (44-57) 87 (75-100) 2b UK sequence separate-slopes binomial GLMM (1|LTLA/OBS) + REGION * DATE UK avg.”
BackgroundInfluentialAssessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901
Self-citationVolz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611
Metadata
- Authors
- Hodcroft, E. B., Zuber, M., Nadeau, S., Vaughan, T. G., Crawford, K. H. D., Althaus, C. L., Reichmuth, M. L., Bowen, J. E., Walls, A. C., Corti, D., Bloom, J. D., Veesler, D., Mateo, D., Hernando, A., Comas, I., González Candelas, F., SeqCOVID-SPAIN consortium, Stadler, T., & Neher, R. A.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2020-10-28
- OpenAlex
- W3094918064
- Cited by
- 323
- References
- 46
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.